Prelude Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Prelude Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,738	Closed	-$103K	–	1234
2023 Q3	$103K	Buy	+10,738	New	+$110K	0.01%	992
2020 Q1	–	Sell	-184	Closed	-$3K	–	1739
2019 Q4	$3K	Buy	+184	New	+$2.4K	﹤0.01%	1809
2019 Q3	–	Sell	-69	Closed	-$2K	–	1884
2019 Q2	$2K	Sell	69 -628	-90%	-$14.7K	﹤0.01%	1573
2019 Q1	$20K	Buy	697 +100	+17%	+$2.17K	﹤0.01%	1314
2018 Q4	$12K	Sell	597 -59	-9%	-$1.19K	﹤0.01%	1336
2018 Q3	$15K	Sell	656 -378	-37%	-$5.11K	﹤0.01%	1371
2018 Q2	$8K	Buy	1,034 +734	+245%	+$6.48K	﹤0.01%	1518
2018 Q1	$3K	Buy	+300	New	+$3.14K	﹤0.01%	1437

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Prelude Capital Management's KALV Position: Q4 2023 in Review

Prelude Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q4 2023, closing a stake of 10,738 shares — an estimated $103K sold.

Prelude Capital Management first reported a position in KALV in Q1 2018 and held it in 8 quarters. The position peaked at $103K in Q3 2023. 93 funds tracked by Wall St. Rank hold KALV as of Q4 2023.

Prelude Capital Management reported no remaining KalVista Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Prelude Capital Management sold 10,738 KalVista Pharmaceuticals shares in Q4 2023, an estimated $103K.
Prelude Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2018 and held it in 8 quarters.
Prelude Capital Management's KalVista Pharmaceuticals position peaked at $103K in Q3 2023.
93 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.